Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Deloitte
Medtronic
Moodys
Colorcon
Julphar
Covington
US Department of Justice
Farmers Insurance
US Army

Generated: August 18, 2017

DrugPatentWatch Database Preview

Forest Labs Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS, and what generic alternatives to FOREST LABS drugs are available?

FOREST LABS has forty-one approved drugs.

There are forty-seven US patents protecting FOREST LABS drugs and there have been three Paragraph IV challenges on FOREST LABS drugs in the past three years.

There are four hundred and fifty-seven patent family members on FOREST LABS drugs in fifty-two countries.

Summary for Applicant: Forest Labs

Patents:47
Tradenames:40
Ingredients:27
NDAs:41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-006Jul 13, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Forest Labs
SUS-PHRINE SULFITE FREE
epinephrine
INJECTABLE;INJECTION007942-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-002Aug 27, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Llc
NAMENDA
memantine hydrochloride
SOLUTION;ORAL021627-001Apr 18, 2005► Subscribe► Subscribe
Forest Labs Inc
URSO 250
ursodiol
TABLET;ORAL020675-001Dec 10, 1997► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-001Aug 14, 2002► Subscribe► Subscribe
Forest Labs Inc
RECTIV
nitroglycerin
OINTMENT;INTRA-ANAL021359-001Jun 21, 2011► Subscribe► Subscribe
Forest Labs Llc
NAMENDA
memantine hydrochloride
TABLET;ORAL021487-001Oct 16, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FOREST LABS drugs

Drugname Dosage Strength Tradename Submissiondate
linaclotide
Capsules145 mcg and 290 mcg
LINZESS
8/30/2016
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules14 mg/10 mg and 28 mg/10 mg
NAMZARIC
5/18/2015
vilazodone hydrochloride
Tablets10 mg, 20 mg, and 40 mg
VIIBRYD
1/21/2015
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
Capsules140 mg/125 mg/ 125 mg
PYLERA  
8/12/2014
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
8/16/2013
asenapine maleate
Sublingual Tablets5 mg and 10 mg
SAPHRIS
8/13/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg
NAMENDA XR
6/17/2013
memantine hydrochloride
Extended-release Capsules28 mg
NAMENDA XR
6/12/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
6/10/2013
mesalamine
Suppository1000 mg
CANASA
5/24/2013
nebivolol hydrochloride
Tablets2.5 mg, 5 mg, 10 mg, and 20 mg
BYSTOLIC
12/19/2011
memantine hydrochloride
Tablets5 mg and 10 mg
NAMENDA
10/16/2007
escitalopram oxalate
Capsules5 mg
LEXAPRO
8/17/2005
escitalopram oxalate
Capsules10 mg and 20 mg
LEXAPRO
3/30/2005

Non-Orange Book Patents for Forest Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,005,452Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug► Subscribe
2,012,045,508► Subscribe
7,772,188Methods and compositions for the treatment of gastrointestinal disorders► Subscribe
8,927,552Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,981,894Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Drugs

Country Document Number Estimated Expiration
Russian Federation2445952► Subscribe
World Intellectual Property Organization (WIPO)2006024018► Subscribe
Mexico2011001620► Subscribe
Canada2779711► Subscribe
Japan2010132687► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Forest Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02C/035Belgium► SubscribePRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
90024-6Sweden► SubscribePRODUCT NAME: LINAKLOTID; REG. NO/DATE: EU/1/12/801/001 20121126
50031Netherlands► SubscribePRODUCT NAME: NEVIVOLOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HYDRO - CHLORIDE; REGISTRATION NO/DATE: RVG 19317 19951018
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Boehringer Ingelheim
Baxter
McKinsey
Covington
Argus Health
Cerilliant
Medtronic
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot